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Background: The economic and social costs of obesity are estimated to be considerable, particularly for inpatient
care. The aim of this study was to compare the hospitalization rates of individuals with severe (body mass index
[BMI] ≥40 kg/m2) or complicated (BMI ≥30 kg/m2) obesity with those of the general population in two regions of
Northwest Italy, and to describe absolute costs of hospitalization and their determinants.
Methods: Between 1996 and 2002, 6,516 patients who were admitted for the first time to a hospital offering a
nutritional rehabilitation programme for obesity were enrolled and followed-up (mean follow-up time: 7.3 years).
Standardized hospitalization rates (SHRs) were computed by sex for all-cause and cause-specific hospitalization. The
general population of the two regions was used as the reference population. The annual cost of hospitalization was
estimated for the study cohort only at the individual level, and its association with different determinants was
assessed using a multivariable linear model for longitudinal data.
Results: SHRs of the study cohort versus the general population increased for all-cause hospitalization (males: 3.53,
95% CI 3.45-3.61; females: 3.22, 95% CI 3.18-3.26) as well as for most obesity-related conditions. The absolute
median annual cost of hospitalization was 2,436 euros for males and 2,293 euros for females. Older age at cohort
enrolment, BMI ≥40 kg/m2, waist circumference above the median (males: 1.26 metres; females: 1.13 metres), and
the presence of co-morbidities, such as cardiovascular diseases, respiratory diseases, cancer, diseases of the
musculoskeletal system and connective tissue, and mental disorders, significantly increased the absolute median
annual costs of hospitalization.
Conclusions: The economic consequences of high hospitalization rates in obese individuals are relevant. Reducing
the occurrence of co-morbidities among obese persons may be one important goal, not only for clinical reasons,
but also from a public health point of view.
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Obesity (body mass index [BMI] ≥30 kg/m2), and high-
grade, or severe obesity (BMI ≥40 kg/m2) have been as-
sociated with increased all-cause mortality in Northern
Europe [1,2] and the United States [3-6]. An Italian co-
hort study of individuals with severe obesity [7] showed
a three-fold increase in overall mortality in males and a
more than two-fold increase in females.* Correspondence: enrica.migliore@cpo.it
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reproduction in any medium, provided the orObese adults are at increased risk of several diseases, in-
cluding cardiovascular diseases (CVDs), diseases of the
musculoskeletal system, diabetes, depression, and some
types of cancer including cancers of the colon-rectum,
pancreas, breast (in postmenopausal women), oesophageal
adenocarcinoma, endometrium, kidney and liver, and
non-Hodgkin lymphoma [8-10]. In addition to increased
mortality and impaired quality of life, obesity and its asso-
ciated co-morbidities may have a considerable impact on
healthcare consumption. Indeed, the hospitalization rates
of overweight and obese adults have been reported to be
higher than those of the general population [11-13].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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are estimated to be considerable, particularly for in-
patient care [14]. Obese persons consume more medica-
tion and healthcare resources, and therefore have higher
costs for drugs and hospitalizations [15-18], and higher
overall healthcare costs compared with normal-weight
individuals [19].
The most widely used indices of body shape are BMI
and waist circumference (WC) [20]. A strong association
between BMI and higher healthcare consumption and
costs has been reported [21-23]. Moreover, healthcare
costs for a given BMI were found to be related to abdom-
inal adiposity, as assessed by WC [24]. Due to the ever-
increasing burden that obesity is putting on healthcare
resources, especially for inpatient care, detailed informa-
tion on the hospitalization of obese individuals may be
useful in planning healthcare programmes tailored to their
specific needs.
The existence of the National Health Service (NHS) in
Italy offers the opportunity to study hospitalization pat-
terns, as all Italian residents are entitled to access any
NHS hospital free of charge, and without administrative
limitations. Healthcare providers, both public and pri-
vate, need to deliver a hospital discharge record (HDR)
database in order to receive reimbursement from the
NHS. All inpatient and day-care activity is then included
in a regional HDR database for administrative purposes.
Using the regional HDR database, the aim of this study
was to compare the hospitalization rates of individuals
with severe (BMI ≥40 kg/m2) or complicated (BMI ≥30
kg/m2) obesity against those of the general population,
and to describe absolute hospitalization cost and their
determinants.
Methods
The study cohort included patients admitted to either
the Medical Ward, or the Obesity Rehabilitation Unit of
the Italian Auxologic Institute (IAI) in Piancavallo, a
specialized centre for the treatment of obesity and its
complications. To be admitted to the IAI, patients had
to have a BMI of either ≥40 kg/m2, or 30–39 kg/m2 with
complications that were not satisfactorily controlled with
outpatient treatment.
The study was a clinical audit that monitored patterns
of care delivered to obese patients after their discharge
from the IAI. Therefore, according to the local ethical
committee, at the time the study was started, ethical ap-
proval was not required. Data anonymization has been
guaranteed by working with encrypted personal identifi-
cation codes.
Inclusion criteria were first admission to the IAI be-
tween 1996 and 2002, age ≥18 years and residence in the
Piedmont or Lombardy Region. For each cohort mem-
ber, all admissions to any NHS-funded hospital afterenrolment were identified from the regional HDR data-
base by a deterministic record-linkage procedure based
on tax identification number. Deaths in the study cohort
were identified through the regional HDR database, in
which deaths during a hospital stay are recorded. All
other cohort members were assumed to be alive at the
end of follow-up, i.e. 31 December 2006. Cohort mem-
bers contributed person-years of follow-up from their
date of enrolment (date of first admission to IAI) until
date of death, or the end of follow-up.
For each individual hospitalization, the underlying
cause was derived from the principal diagnosis contained
in the HDR database, coded according to the Inter-
national Classification of Diseases, 9th revision (ICD-9).
The following diagnostic categories were used: all CVDs
(390–459), hypertensive disease (401–405) and ischemic
heart disease (410–414), heart failure (428), all respira-
tory diseases (460–519), pneumonia and influenza (480–
487), chronic bronchitis (491), asthma (493), all malig-
nant neoplasms (140–208), colon-rectum neoplasms
(153–154), breast neoplasms (174–175), all diseases of
the musculoskeletal system and connective tissue (710–
739), all mental disorders (290–319), diabetes (250),
obesity (278) and rehabilitation procedures (V57). A re-
sidual category with all other diagnoses was also defined.
Diabetes was assessed by integrating all available infor-
mation: ICD-9 code 250 in any diagnostic field of all
available discharge records, or insulin or anti-diabetic
therapy at cohort enrolment, or fasting glucose level at
cohort enrolment of ≥125 mg/dl. Hypertension was con-
sidered present if ICD-9 codes 401–405 were present in
any of the diagnostic fields of any discharge record.
The following clinical data and general risk factors
were abstracted from the clinical records of the first
admission to the IAI: height, weight, BMI and WC, sys-
tolic and diastolic blood pressure, fasting glucose, total
cholesterol, low-density lipoprotein cholesterol and
high-density lipoprotein cholesterol, triglycerides, to-
bacco smoking (any current use) and alcohol consump-
tion. (any current consumption). Educational level and
marital status were obtained from the regional HDR
database.
The general population of the Piedmont [http://www.
ruparpiemonte.it/infostat/] and Lombardy [http://www.
asr-lombardia.it] Regions during the study period served
as the reference population for the analysis of
hospitalization rates (about 6.5 million inhabitants). The
proportion of obese individuals in the adult population
of all the regions of Northwest Italy has been estimated
at around 8%-10% [25,26].
Diagnosis Related Group (DRG) tariffs, which repre-
sent the reimbursement levels of the NHS to healthcare
providers, were used to estimate hospitalization costs.
Tariffs from before 2001 were converted into Euros, and
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the general Consumer Price Index.
Statistical analysis
Standardized hospitalization rates (SHRs) and their
corresponding 95% confidence intervals (CIs) were cal-
culated as the ratio of observed to expected hospitaliza-
tions. Observed hospitalizations did not include the
admission at cohort enrolment. The expected hospitali-
zations were obtained by applying the age-, sex- and
year-specific hospitalization rates of the reference popu-
lation. SHRs by sex were computed for all-cause, and for
cause-specific hospitalization, as per the diagnostic cat-
egories previously described. SHRs for diabetes (250),
obesity (278) and rehabilitation procedures (V57) are
not reported, as these conditions are either specific to,
or very closely associated with obesity. All SHR analyses
were stratified by BMI (30–39 kg/m2 and ≥40 kg/m2)
and WC (below versus above the median: 1.26 m in
males, 1.13 m in females), as indicators of the severity of
obesity. SHRs for all-cause hospitalizations were also
stratified by age group (18–29, 30–39, 40–49, 50–59,
60–69, and ≥70 years).
The absolute number of hospitalizations due to obesity
was calculated as the difference between the observed
and expected events. Attributable Risk (AR%) i.e., the
proportion of observed hospitalizations that would have
been avoided if cohort members had the same body
weight distribution as the general population, was esti-
mated as:
SHR 1ð Þ=SHRð Þ  100
Individual cumulative costs of hospitalizations during
follow-up were calculated by summing the DRG tariffs
corresponding to the hospital stays of each cohort mem-
ber. The average annual costs of hospitalization were
calculated by dividing this sum by the length of follow-
up in years. The association between average annual
costs of hospitalization and their determinants was
estimated via a multivariable Gamma Generalized Esti-
mating Equations model with log link, assuming a
first-order autoregressive correlation between costs for
the same cohort member from the first to the last
hospitalization. This structure is appropriate for longitu-
dinal studies when the correlation between subsequent
measurements is expected to decline with time. Esti-
mates were weighted by the time of exposure as an off-
set of the logarithm of time in years and inserted in the
linear predictor of the model.
Covariates included in the multivariable model, along
with BMI, WC and age at cohort enrolment, were in
principle all socio-demographic and clinical variables,
but blood pressure, total cholesterol and triglycerideshad to be excluded due to collinearity. The model also
included co-morbidities identified in discharge records
during follow-up. As diabetes does not usually entail in-
patient treatment, and is associated with CVDs, a term
was also added to model the interaction between dia-
betes and CVDs. All analyses were stratified by sex. Re-
sults are presented as the exponentiation of the coefficients,
which can be interpreted as relative risks.
Record linkage and data management were carried out
using SAS Release 8.02 (SAS Institute, Cary, North
Carolina, USA). All analyses were conducted using STATA
9 (Stata Corporation, College Station, Texas, USA).
Results
Table 1 shows the general characteristics of the study co-
hort. Out of 6,516 cohort members, 77.9% were females.
Mean age at cohort enrolment was 48.9 years (standard
deviation 14.0) for males and 51.2 years (standard devi-
ation 14.8) for females. Half of the cohort members
(53.2% females and 48.4% males) had a BMI of ≥40 kg/
m2 (Table 1).
The mean follow-up time was 7.3 years, with 45,398
person-years of observation (10,005 for males and
35,393 for females). During follow-up 37,983 hospital
admissions were identified (77.2% among females), with
a median number of four hospitalizations per cohort
member, regardless of sex (interquartile range: 2–7).
Thirty-seven percent of all hospitalizations had a
principle diagnosis of endocrine, nutritional and meta-
bolic diseases recorded in the regional HDR database.
The other most frequent diagnoses were: CVDs (9.2%),
rehabilitation procedures (6.6%) and mental disorders
(5.1%). A complete list of diagnoses, corresponding to
the principal diagnosis recorded in the HDR database
for each hospitalization, is reported in Additional file 1:
Table S1.
Among males, SHRs were higher in the 30-49-year age
group. In women, the highest SHR was observed in the
50-59-year age group, and it was less pronounced than
among men. In both sexes, the absolute number of hos-
pitalizations due to obesity was largest between 50 and
69 years, and BMI ≥40 kg/m2 and WC above the median
were associated with higher SHRs (Table 2).
CVDs were the most frequent cause of hospitalization
in this study cohort. The proportion of hospitalizations
due to obesity was particularly high for heart failure
(around 81% in both genders) and for hypertensive dis-
ease (89% in males and 79% in females). Hospitalization
for respiratory diseases was four-fold higher among co-
hort members compared to the general population. In
particular, cohort members with BMI ≥40 kg/m2 or with
WC above the median had a more than a five-fold in-
crease in hospitalization rates. The highest SHR was
found for chronic bronchitis, with a proportion of
Table 1 Socio-demographic and clinical characteristics of the study cohort
Males Females
N (1,440) % N (5,076) %
Age at cohort enrolment (years)
18-29 154 10.7 558 11.0
30-39 224 15.6 622 12.3
40-49 305 21.2 882 17.4
50-59 396 27.5 1,356 26.7
60-69 281 19.5 1,171 23.1
≥70 80 5.6 487 9.6
Calendar period of enrolment
1996-1999 210 14.6 757 14.9
2000-2003 698 48.5 2,378 46.8
2004-2006 532 36.9 1,941 38.2
Educational level
High 559 38.8 1,421 28.0
Intermediate 596 41.4 1,783 35.1
Low 268 18.6 1,725 34.0
Unknown 17 1.2 147 2.9
Marital status
Married 961 66.8 3,361 66.2
Other 477 33.2 1,714 33.8
N mean (SD) N mean (SD)
Height (cm) 1,440 172.2 (7.4) 5,076 157.5 (7.0)
Weight (kg) 1,440 121.3 (21.7) 5,076 102.5 (17.0)
BMI (kg/m2) 1,440 40.9 (6.4) 5,076 41.4 (6.6)
WC (cm) 1,402 127.4 (0.37) 5,005 113.7 (0.18)
Systolic blood pressure (mm/Hg) 1,438 142.1 (19.2) 5,038 138.9 (20.1)
Diastolic blood pressure (mm/Hg) 1,438 85.3 (10.9) 5,044 82.7 (10.5)
Fasting glucose (mg/dl) 1,432 110.1 (43.8) 5,065 100.6 (33.5)
Total cholesterol (mg/dl) 1,431 213.3 (44.2) 5,066 214.9 (43.2)
LDL cholesterol (mg/dl) 1,312 135.8 (36.2) 4,924 137.4 (50.7)
HDL cholesterol (mg/dl) 1,429 41.4 (12.3) 5,059 50.9 (13.2)
Triglycerides (mg/dl) 1,430 167 (122–235)* 5,062 128 (96–173)*
Current smoker (%) 1,416 32.1 5,002 21.2
Any alcohol consumption (%) 1,424 40.0 5,029 16.7
*median (interquartile range).
N number, SD standard deviation, BMI body mass index, WC waist circumference, LDL low-density lipoprotein, HDL high-density lipoprotein.
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both sexes (Table 3). Only females had a significant ex-
cess of hospitalizations for all malignant neoplasms.
Overall, hospitalizations due to diseases of the musculo-
skeletal system and connective tissue were significantly
more frequent in cohort members than in the general
population. Obesity was also associated with mental dis-
orders in both sexes, particularly in females with a WC
above the median (Table 3).The median and mean annual costs of hospitalization
are fully reported in Additional file 1: Table S2. Higher
age at recruitment, BMI ≥40 kg/m2, WC above the me-
dian, and the presence of several co-morbidities were all
associated with an increase in average annual costs of
hospitalization (Additional file 1: Table S2).
Results of the multivariable analysis are shown in
Table 4. Age was associated with a small increase in
costs each year in both sexes. BMI did not significantly
Table 2 SHR and 95% CI of all-cause hospitalizations by sex, age group, BMI and WC at recruitment
Males (py=10,004) Females (py=35,393)
Hospitalizations due to obesity Hospitalizations due to obesity
O SHR 95% CI O-E AR% O SHR 95% CI O-E AR%
All-cause hospitalizations 7,231 3.53 3.45-3.61 5,183.3 71.7 24,236 3.22 3.18-3.26 16,704.3 68.9
Age group (years)
18-29 362 3.69 3.33-4.10 264.0 72.9 1,357 3.31 3.13-3.49 946.4 69.8
30-39 760 5.04 4.70-5.41 609.2 80.2 2,418 2.97 2.85-3.09 1,603.3 66.3
40-49 1,065 5.03 4.74-5.34 853.2 80.1 3,180 3.46 3.34-3.58 2,259.9 71.1
50-59 2,087 4.17 4.00-4.35 1,586.5 76.0 5,929 3.81 3.72-3.91 4,373.7 73.8
60-69 2,017 3.14 3.01-3.29 1,375.5 68.2 7,012 3.43 3.35-3.51 4,965.3 70.8
≥70 940 2.11 1.98-2.25 494.8 52.6 4,340 2.43 2.36-2.51 2,555.5 58.8
BMI (kg/m2)
30.0-39.9 plus complications 3,581 3.14 3.04-3.25 2,440.9 68.2 10,684 3.02 2.97-3.08 7,148.0 66.9
≥40.0 3,650 4.02 3.89-4.15 2,742.3 75.1 13,552 3.39 3.34-3.45 9,556.3 70.5
WC (cm)
≤50th percentile 3,299 3.14 3.04-3.25 2,249.8 68.2 11,468 2.97 2.92-3.02 7,605.6 66.3
>50th percentile 3,698 3.93 3.81-4.06 2,757.9 74.6 12,351 3.49 3.43-3.55 8,810.2 71.3
SHR standardized hospitalization ratio, 95% CI confidence interval, py person years; O observed; E expected, AR% attributable risk %, BMI body mass index, WC
waist circumference (median value for males=126 cm; median values for females=113 cm).
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every 10 cm increase in WC was positively associated
with an 8% increase in costs among females (Table 4).
Among males the presence of respiratory diseases in-
creased the average annual costs of hospitalization by
40% (95% CI: 10%-79%), malignant neoplasms by 25%Table 3 Hospitalizations for CVDs, respiratory diseases, all ma
connective tissue, and mental disorders
Males (py=10
Causes of hospitalization (ICD-9 code) O SHR 95% CI
All CVDs (390–459) 1,250 3.46 3.27-3.66
- Hypertensive disease* (401–405) 99 5.38 4.42-6.55
- Ischemic heart disease (410–414) 321 2.79 2.50-3.11
- Heart failure (428) 228 9.11 8.00-10.4
Respiratory diseases (460–519) 500 4.02 3.68-4.38
- Pneumonia and influenza (480–487) 42 1.86 1.38-2.52
- Chronic bronchitis (491) 143 7.32 6.21-8.62
- Asthma (493) 18 3.74 2.36-5.94
All malignant neoplasms (104–208) 209 1.13 0.98-1.29
- Colon-rectum (153–154) 19 1.34 0.85-2.10
- Breast (174–175) - - -
Diseases of the musculoskeletal system and
connective tissue (710–739)
421 2.63 2.39-2.89
Mental disorders (290–319) 264 4.99 4.42-5.63
* Diagnosis of hypertensive diseases – ICD9 401–405 – from any of all six diagnosis
CVDs cardiovascular diseases, py person years, ICD-9 International Classification of D
ratio, CI confidence interval, AR% attributable risk %.(95% CI: 4%-51%), CVDs by 22% (95% CI: 7%-39%),
hypertensive disease by 18% (95% CI: 8%-28%) and dis-
eases of the musculoskeletal system and connective tis-
sue by 15% (95% CI: 4%-26%). The same co-morbidities,
with the exception of CVD, were significant predictors






O-E AR% O SHR 95% CI O-E AR%
888.50 71.1 2,220 2.65 2.54-2.76 1,380.70 62.3
80.60 81.4 339 5.35 4.81-5.95 275.60 81.3
206.00 64.2 328 2.42 2.17-2.70 192.50 58.7
203.00 89.0 286 4.82 4.29-5.41 226.70 79.3
375.50 75.1 1,136 3.89 3.67-4.12 844.10 74.3
19.50 46.2 107 1.95 1.62-2.36 52.20 48.7
123.40 86.3 273 7.48 6.64-8.42 236.50 86.6
13.19 73.3 99 4.32 3.55-5.26 76.10 76.9
23.40 11.5 645 1.22 1.13-1.32 118.11 18.0
4.80 25.4 58 1.53 1.18-1.97 20.00 34.6
- - 145 1.13 0.96-1.34 17.20 11.5
260.70 62.0 2,748 3.77 3.63-3.91 2,019.00 73.5
2,110.03 80.0 1,358 6.84 6.49-7.21 1,159.40 85.4
codes in the HDR database.
iseases, 9th revision, O observed, E expected, SHR standardized hospitalization
Table 4 Determinants of average annual costs of hospitalization (multivariable Gamma Generalized Equations Estimate
model with log link)
Males Females
Variables Effect* (95% CI) Effect* (95% CI)
Age (one year) 1.01 (1.00-1.01) 1.01 (1.00-1.01)
WC (10 cm) 0.97 (0.83-1.12) 1.08 (1.02-1.14)
BMI (one unit) 1.01 (0.98-1.04) 0.99 (0.98-1.00)
Hypertensive disease 1.18 (1.08-1.28) 1.21 (1.17-1.26)
Malignant neoplasms 1.25 (1.04-1.51) 1.37 (1.12-1.68)
Respiratory diseases 1.40 (1.10-1.79) 1.24 (1.10-1.38)
Diabetes 0.92 (0.82-1.03) 0.98 (0.90-1.06)
CVDs 1.22 (1.07-1.39) 0.97 (0.89-1.06)
CVDs in cohort members with diabetes** 1.27 (1.14-1.43) 1.35 (1.08-1.69)
Mental disorders 1.06 (0.61-1.85) 1.16 (1.09-1.24)
Diseases of the musculoskeletal system and connective tissue 1.15 (1.04-1.26) 1.45 (1.39-1.51)
* Effect=mean costs ratio, obtained as exponential of model coefficients. Model adjusted for height, educational level, marital status, current cigarette smoking,
and alcohol consumption.
** Test for interaction: males p=0.625; females p=0.007.
CI confidence interval, WC waist circumference, BMI body mass index, CVDs cardiovascular diseases.
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Among females in particular, malignant neoplasms and
diseases of the musculoskeletal system and connective
tissue were stronger predictors of cost, while respiratory
diseases were milder predictors. Females hospitalization
costs were also affected by mental disorders (16%; 95%
CI: 9%-24%). The presence of diabetes was not a pre-
dictor of hospitalization costs, but cohort members with
diabetes had significant increases in hospitalization costs
due to CVDs in both sexes.
Discussion
This study presents hospitalization rates in a cohort of
obese, adult patients recruited in a centre specialized in
the treatment of obesity and its complications, compared
them to those in the general population, and estimated
absolute costs of hospitalization. Hospitalization rates in
this cohort were much higher than in the general popu-
lation, with SHRs increasing according to the severity of
obesity, as measured by BMI or WC. Approximately
70% of all hospitalizations in the cohort were attribut-
able to obesity, and the SHRs for most obesity-related
co-morbidities were significantly increased.
The results presented here on the excess hospitalization
of cohort members with severe obesity compared to the
general population are in line with the results of Keating
et al. on outpatient services and the utilization of pharma-
ceutical therapies [27].
Overall, a comparatively larger effect of obesity on
hospitalization rates among males compared to females
was found, with the highest risk in the age groups 30–39
and 40–49 years. Among females, age-specific hospitaliza-
tions ratios showed less variation. The major differencebetween the sexes was in the age group 30–39 years;
males had the highest and females the lowest SHRs be-
cause of different expected baseline risks, probably due to
maternity-related hospital admissions in the general fe-
male population. In line with Luchsinger et al. [12] and
Queensberry et al. [22], the SHR increase at older ages
(>70 years) was less pronounced in both sexes, even
though the absolute number of hospitalizations due to
obesity remained large in females. The SHR patterns by
sex and age were consistent with the corresponding pat-
terns in standardized mortality ratios described by
Mirabelli et al. [7] in a previous cohort study of patients
with severe obesity.
SHRs were higher in cohort members with severe
obesity and a WC above the median in both sexes, but
differences by category of severity were larger among
males. However, in this study cohort the presence of
complications was a prerequisite for admission to the
IAI for individuals with a BMI of 30–39 kg/m2, but not
with a BMI of ≥40 kg/m2. Consequently, differences in
morbidity between the two BMI groups were likely to
have been attenuated. The capability of WC to identify
patients with a worse prognosis at least as efficiently as
BMI has already been described [28].
Obesity is known to be an independent risk factor for
CVDs [29,30]. Many studies found a positive association
between obesity and CVD-related outcomes [11-13]. In
this study cohort, both sexes presented a higher number
of hospitalizations due to CVDs compared with the gen-
eral population (SHRs approximately 3.5 in males and
2.5 in females). No trend was observed with severity of
obesity, but in this comparison the underestimation of
differences due to the selection criteria applied to the
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ticularly high SHRs (9.1 in males, 4.8 in females) for
heart failure were also observed, most likely due to the
well-established strain induced by obesity on heart func-
tion [29].
Obesity is associated with a wide range of respiratory
conditions, including chronic obstructive pulmonary dis-
ease (COPD), asthma, obstructive sleep apnoea, pulmonary
embolism and aspiration pneumonia [31]. Nevertheless, lit-
tle is known about the burden of hospitalization due to
obesity-related respiratory complications. Han et al. [11]
found no significant difference between the number of
hospital admissions due to pneumonia and COPD in obese
and normal-weight patients. Kornum et al. [32] found an
increased risk of pneumonia-related hospitalization among
males, but the association disappeared after controlling for
other chronic diseases. In this study cohort, hospitaliza-
tions for respiratory diseases were four times more fre-
quent than in the general population. There was a clear,
albeit possibly underestimated, trend in SHRs according to
the severity of obesity in both sexes. COPD had the highest
SHRs, while pneumonia and influenza were only slightly
more frequent than in the general population.
SHRs for cancer, both overall and site-specific, were
not increased in males. In females a slight excess for all
cancers was observed, without any evidence of trends by
BMI or WC, and a small excess for cancers of the
colon-rectum specifically. The association between obes-
ity and cancer incidence and mortality is well established
[10,33-35]. However, it is important to note that this
study included relatively young patients (mean age 50.7)
and a limited median follow-up time of 7.3 years. There-
fore, at present this cohort cannot give information on
cancer hospitalization rates. Similar findings were
reported in the Italian mortality cohort study [7].
Obesity is considered to be one of the most important
risk factors for knee osteoarthritis [36]. A Norwegian co-
hort study [37] also showed a significant association be-
tween obesity and hand osteoarthritis. Weitoft et al. [13]
reported a 50% higher risk of inpatient care for musculo-
skeletal diseases among obese patients than normal-
weight individuals. In the present study cohort, the
SHRs for diseases of the musculoskeletal system and
connective tissue were 2.6 for males and 3.8 for females,
i.e., considerably increased, even if no trend for the
severity of obesity was apparent.
Finally, hospitalizations due to mental disorders were
in excess in this study cohort compared with the general
population, particularly among females (SHR 6.8). Sev-
eral studies [38,39] reported an increased risk of mood
disorders in obese individuals of both sexes. The higher
SHRs among females compared to males may be attrib-
uted to an increased susceptibility to some disorders,
such as bipolar disorders and social phobia [40].SHRs for obesity, diabetes and rehabilitation were not
reported for several reasons. First, these diagnoses are
strongly associated with severe obesity. Second, diabetes
is considered by the NHS as an inappropriate cause of
hospital admission. Conversely, severe obesity can justify
diabetes as a principle diagnosis in the HDR database.
Consequently, SHRs for diabetes in the study cohort ver-
sus the general population could be over-estimated due
to a differential attitude in filling discharge records.
Third, the admissions due to rehabilitation procedures
are likely to be partially covered by the first admission to
the IAI.
It is important to point out that relative measures of
association, such as SHRs, should be read in combin-
ation with absolute numbers to fully understand the
burden of disease induced by obesity. Indeed, if con-
sidered independently, these two measures may be
misleading. The hospital admissions patterns described
in the present report determined a per-person mean
annual cost of hospitalization of more than 3,000
euros. Since all cohort members were enrolled during
a first admission to the IAI in Piancavallo, they all had
at least one hospital admission, and non-zero costs of
hospitalization.
The main determinants of hospitalization costs were
analysed to quantify their contribution to the cost accu-
mulation. The economic burden due to hospital use was
highly affected by the presence of co-morbidities. Malig-
nant neoplasms, respiratory diseases, hypertensive dis-
eases and diseases of the musculoskeletal system and
connective tissue were predictive of higher annual costs
of hospitalization in both sexes. CVDs were a relevant
cost determinant only for males, with a 24% increase in
annual costs of hospitalization, whereas costs increased
by 16% with the presence of mental disorders among
females only.
Diabetes was not a significant determinant of hos-
pitalization costs, but diabetes per se was expected to be
a driver mainly of drug costs and outpatient care.
Hospitalization of cohort members with diabetes was usu-
ally due to age and diabetes-related complications, mainly
CVD. In fact, among cohort members with diabetes,
CVDs were found to be a significant predictor of higher
hospitalization costs in both sexes.
In the study cohort, the severity of obesity, as de-
scribed by BMI, did not affect hospitalization costs. This
result is in contrast to Andreyeva et al. [21], who de-
scribed an increase in healthcare expenditures among
moderate to severely obese males and among severely
to extremely obese females. Other previous studies
[19,22] on BMI and healthcare expenditures are not
comparable with the observations in the present study,
as they used the BMI of normal-weight patients (BMI
20–25 kg/m2) as a reference. The cohort selection
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costs in the present study by reducing the differences
associated with BMI. WC was a significant predictor of
hospitalization costs among females, with an 8% in-
crease in costs for every 10 cm increase in WC. Previ-
ous studies suggested that abdominal adiposity may be
a better predictor of healthcare costs than BMI [24,41].
The main strength of this study was that it was based on
a large cohort, with baseline information available on sev-
eral well-recognized risk factors for subsequent morbidity
and mortality, including smoking, alcohol consumption,
and various clinical parameters, which allowed us to ad-
just for potential confounders. However, a number of
limitations must be considered when interpreting the
results of this study. First, the vital status of cohort
members was not systematically ascertained. Cohort
members who died during a hospital stay could be
identified, but all others were assumed to be living
throughout the observation period. As a consequence,
overestimation of the person-years in the study cohort
may have occurred, and led to an underestimation of
SHRs, even if the low mean age of cohort members is
likely to have kept any underestimation small. Second,
the cohort was enrolled at a specialized centre, and
therefore should not be assumed to be representative of
the overall obese population in Italy. Nevertheless, as
the IAI offers a residential nutritional rehabilitation
programme, but not active treatment of obesity (such
as bariatric surgery) or of complications due to obesity,
the impact on subsequent hospitalization patterns due
to complications is likely to be limited.
Reported hospitalization rates have been standardized
by age, sex and calendar year. A potential confounder
of hospital use could be socioeconomic status. Never-
theless, due to the lack of information in the general
population dataset, it was not possible to adjust for so-
cioeconomic status.
Finally, costs were calculated using DRG tariffs, which
are used to reimburse healthcare providers. DRG tariffs
do not represent actual costs, but standard costs. While
obese people have been reported to experience longer
hospital stays [42], and to be likely to require more re-
sources compared with normal-weight individuals af-
fected by the same diseases, the DRG tariffs did not vary
based on the presence of obesity, and therefore real costs
were probably underestimated.
Conclusions
The economic consequences of the high hospitalization
rates of obese individuals are important. The role of
obesity-related co-morbidities on cost accumulation sug-
gests that secondary prevention programmes to reduce
the occurrence of these co-morbidities may not only be
beneficial to obese people, but could also controlhospitalization costs. As such, further study on their eco-
nomic impact is warranted. Of course, the importance of
health promotion programmes aimed at preventing obes-
ity in the general population is unquestioned.
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